专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

EP0437547B1 MONOCLONAL ANTIBODIES AGAINST RECEPTOR-INDUCED BINDING SITES ON LIGANDS BINDING TO PROTEINS OF THE CYTOADHESIN SUPER FAMILY 失效转让
标题翻译： AGAINST受体结合诱导的SITES ON配体与蛋白CYTOADHESIN-SUPER FAMILY TIE单克隆抗体
公开(公告)号：EP0437547B1
公开(公告)日：1999-12-29
申请号：EP90900499.6
申请日：1989-10-02
申请人： THE SCRIPPS RESEARCH INSTITUTE
发明人： PLOW, Edward, F. , GINSBERG, Mark, H.
IPC分类号： C12N5/20 , C07K16/00 , C07K16/36 , A61K39/395 , G01N33/536 , G01N33/567
CPC分类号： C07K16/36 , A61K38/00
摘要： Receptor-induced binding sites (RIBS) expressed in a ligand when that ligand is bound in a complex with a receptor are disclosed, as are monoclonal antibodies that immunoreact with a RIBS but do not substantially immunoreact with either the ligand or the receptor when free in solution, and hybridomas that secrete such monoclonal antibodies. Anti-RIBS monoclonal antibodies, hybridomas secreting those antibodies, as well as methods of making and using such antibodies are particularly illustrated in regard to RIBS expressed by fibrinogen when that ligand is bound by the GPIIb/IIIa receptor molecule.

82. 发明公开

EP0878551A2 Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes 失效
标题翻译： Erhöhungder FVII Empfindlichkeit eines Thromboplastinreagenzes
公开(公告)号：EP0878551A2
公开(公告)日：1998-11-18
申请号：EP98107162.4
申请日：1998-04-20
申请人： Dade Behring Marburg GmbH
发明人： Wissel, Thomas, Dr. , Keuper, Hermann, Dr. , Nettelhoff, Hubert, Dr. , Kandel, Heinz-Georg , Muth, Reiner , Kraus, Michael, Dr.
IPC分类号： C12Q1/56 , C07K16/36
CPC分类号： G01N33/86 , C12Q1/56 , G01N2333/96447
摘要： Die vorliegende Erfindung betrifft ein Verfahren zur Erhöhung der F VII Empfindlichkeit eines Thromboplastinreagenzes durch eine Wärmebehandlung.
摘要翻译：增加凝血激酶试剂的因子VII敏感性的方法包括选择性地抑制试剂中的因子VII / VIIa活性。还要求的是制备抑制组织因子VIIa-复合物的凝血起始活性的多克隆抗体。

83. 发明授权

EP0561427B1 Monoclonal antibodies to new factor VIII coagulant polypeptides 失效
标题翻译：针对新颖因子VIII Gerinnungspolypeptide单克隆抗体
公开(公告)号：EP0561427B1
公开(公告)日：1997-07-16
申请号：EP93108007.1
申请日：1984-04-02
申请人： THE SCRIPPS RESEARCH INSTITUTE
发明人： Zimmerman, Theodore S. , Fulcher, Carol A.
IPC分类号： C07K16/36 , C12N5/20
CPC分类号： C07K14/755 , A61K38/00 , C07K16/36

84. 发明公开

EP0640621A3 Anti-thrombin monoclonal antibody 失效
标题翻译：单克隆抗体凝血酶。
公开(公告)号：EP0640621A3
公开(公告)日：1996-03-06
申请号：EP94306112.7
申请日：1994-08-18
申请人： ORIENTAL YEAST CO., LTD.
发明人： Nishino, Masato, 17-47, Shimoshinjo 5-chome , Yamagata, Yoshiki , Fujita, Tsuyoshi
IPC分类号： C07K16/36 , C12N5/12 , G01N33/577
CPC分类号： C07K16/40
摘要： A novel anti-thrombin monoclonal antibody is prepared by using thrombin-antithrombin III complex (TAT) as an antigen; by using the monoclonal antibody, rapid, exact and simple immunoassay for not only TAT but also thrombin itself is possible.

85. 发明公开

EP0123945A1 New factor VIII coagulant polypeptides 有权转让
标题翻译： Faktor VIII Polypeptidkoagulantien und monoklonaleAntikörpergegen diese。
公开(公告)号：EP0123945A1
公开(公告)日：1984-11-07
申请号：EP84103630.4
申请日：1984-04-02
申请人： THE SCRIPPS RESEARCH INSTITUTE
发明人： Zimmerman, Theodore S. , Fulcher, Carol A.
IPC分类号： C12N9/50 , C07K16/36 , A61K38/00 , A61K35/16 , C12P21/00 , C12N15/00
CPC分类号： C07K14/755 , A61K38/00 , C07K16/36
摘要： Polypeptides have been discovered which exhibit high specific VIII : C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.
摘要翻译： 1个或更多个多肽（I）在pt处显示手。对应于100。先生 92,000个或在pts的乐队。对应于100。对先生的价值观 92,000，约 80,000和约 79000; 的约 92,000，约 72,000和约 71000; 或约 92,000，约 80,000，约 79,000，约 72,000和约71,000; 当进行十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳。凝血剂具有超过1800U / mg的特异性结合活性，该活性在连续的至少约5天内显示。 10分钟并且凝血剂表现出人因子VIII：C抗体结合能力。 IgG单克隆抗体由通过将来自小鼠骨髓瘤的细胞与先前用人因子VIII：C免疫的小鼠的脾细胞融合而形成的杂交瘤产生。抗体与人因子VIII：C反应并显示以下反应之一。（a）与92,000先生，18万岁以上的多肽和54,000岁以下的多肽反应，不与44,000,71,000,72,000,79,000,80,000元的那些反应; （b）对92,000，100,000或以上和4.4万元的多肽作出反应，不与54,000,71,000,72,000,79,000,80,000等的那些反应; （c）对79,000,80,000和100,000或更高的多肽进行反应，并且与44,000,54,000,71,000,72,000,92,000元的那些不反应; （d）对108,000以上的多肽进行反应，但与Mr以下108,000以下的多肽无关。

86. 发明公开

EP4433088A1 DOSING REGIMENS OF FACTOR XI/XIA ANTIBODIES 审中-实审
公开(公告)号：EP4433088A1
公开(公告)日：2024-09-25
申请号：EP22896760.0
申请日：2022-11-18
申请人： Anthos Therapeutics, Inc.
发明人： FREEDHOLM, Debra A. , BLOOMFIELD, Daniel M. , GLASSPOOL, Royston J. , FREEMAN, Jonathan E. , KHDER, Yasser
IPC分类号： A61K39/395 , A61K9/08 , A61P7/02 , C07K16/36
CPC分类号： A61P7/02 , C07K16/36 , A61K2039/50520130101 , A61K2039/54520130101 , A61K2039/5420130101

87. 发明公开

EP4313296A1 REDUCING SURGERY-ASSOCIATED HEMOLYSIS IN COLD AGGLUTININ DISEASE PATIENTS 审中-实审
公开(公告)号：EP4313296A1
公开(公告)日：2024-02-07
申请号：EP22723240.2
申请日：2022-03-31
申请人： Bioverativ USA Inc.
发明人： HOBBS, William, E. , STOREK, Michael, J. , TVEDT, Tor Henrik Anderson , WARDECKI, Marek , WONG, Nancy
IPC分类号： A61P7/04 , C07K16/36 , A61K39/00

88. 发明公开

EP4218816A3 PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII 审中-实审
公开(公告)号：EP4218816A3
公开(公告)日：2023-09-13
申请号：EP23157462.5
申请日：2015-03-31
申请人： Chugai Seiyaku Kabushiki Kaisha
发明人： YONEYAMA, Koichiro
IPC分类号： A61K39/395 , A61P7/04 , C07K16/36 , C07K16/46
摘要： The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.

89. 发明公开

EP4218816A2 PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII 审中-实审
公开(公告)号：EP4218816A2
公开(公告)日：2023-08-02
申请号：EP23157462.5
申请日：2015-03-31
申请人： Chugai Seiyaku Kabushiki Kaisha
发明人： YONEYAMA, Koichiro
IPC分类号： A61K39/395 , A61P7/04 , C07K16/36 , C07K16/46
摘要： The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.

90. 发明公开

EP4175669A1 HIGH CONCENTRATION FORMULATION OF FACTOR XII ANTIGEN BINDING PROTEINS 审中-实审转让
公开(公告)号：EP4175669A1
公开(公告)日：2023-05-10
申请号：EP21834598.1
申请日：2021-07-05
申请人： CSL Innovation Pty Ltd
发明人： JOHNSTON, Michael , GOODALL, Dianna Grace , EDWARDS, Nathan Aaron
IPC分类号： A61K39/395 , A61P7/02 , C07K16/36 , A61K47/18 , A61K47/22 , A61K9/08

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式